Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy

Blood Adv. 2020 Dec 8;4(23):6019-6022. doi: 10.1182/bloodadvances.2020003176.

¹ Department of Internal Medicine and.
² Department of Hematology Oncology, MedStar Washington Hospital Center, Washington, DC.
³ Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
⁴ Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD; and.
⁵ Department of Neurology, George Washington University, Washington, DC.

Abstract

CAR T-cell therapy was safe and effective in a DLBCL patient with coexisting autoimmune neuropathy.
CD19 CAR T-cell therapy may control refractory autoantibodies and monoclonal gammopathies.